Skip to main content
Top
Published in: Clinical Rheumatology 4/2009

01-04-2009 | Original Article

The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis

Authors: Ingo H. Tarner, Ulf Müller-Ladner, Christine Uhlemann, Uwe Lange

Published in: Clinical Rheumatology | Issue 4/2009

Login to get access

Abstract

Serial mild whole-body hyperthermia is a widely used balneotherapy modality for clinically inactive ankylosing spondylitis (AS) in rehabilitative medicine. Thus far, the mechanisms of its favorable influence on the symptoms of AS are not completely understood. We therefore analyzed the effect of mild whole-body hyperthermia on the systemic levels of pivotal proinflammatory cytokines. Twelve male subjects with AS and 12 healthy control subjects received nine cycles of whole-body hyperthermia (target body core temperature, 38.5°C; duration, 50 min). Serum samples were taken at the beginning of the last cycle and at 1, 6, and 24 h for measurement of tumor necrosis factor α, interleukin 1β and interleukin 6. Significant differences of cytokine levels were found between both groups. In AS patients, hyperthermia caused a significant reduction of all cytokines by 40–50%. Thus, serial mild whole-body hyperthermia in AS results in heat-induced changes of the proinflammatory cytokine network.
Literature
1.
go back to reference Panush RS (2000) American College of Rheumatology position statement: complementary and alternative therapies for rheumatic disease. Rheum Dis Clin North Am 26:189–192CrossRef Panush RS (2000) American College of Rheumatology position statement: complementary and alternative therapies for rheumatic disease. Rheum Dis Clin North Am 26:189–192CrossRef
2.
go back to reference Hentschel HD, Nold F, Regehr I (1969) Beobachtungen bei der Überwärmungstherapie der ankylosierenden Spondylitis. Verh Dtsch Ges Rheumatol 1:184–188PubMed Hentschel HD, Nold F, Regehr I (1969) Beobachtungen bei der Überwärmungstherapie der ankylosierenden Spondylitis. Verh Dtsch Ges Rheumatol 1:184–188PubMed
3.
go back to reference Bühring M, Bork-Wölwer L, Krippner H, Pirlet K (1977) Quantitative Veränderungen peripherer T-Lymphozyten unter Hyperthermie. MMW Münch Med Wochenschr 119:1591–1594PubMed Bühring M, Bork-Wölwer L, Krippner H, Pirlet K (1977) Quantitative Veränderungen peripherer T-Lymphozyten unter Hyperthermie. MMW Münch Med Wochenschr 119:1591–1594PubMed
4.
go back to reference Bühring M, Bork-Wölwer L, Krippner H (1978) Peripheral T lymphocytopenia under exogenous thermal stress. Cancer 42:2794–2797PubMedCrossRef Bühring M, Bork-Wölwer L, Krippner H (1978) Peripheral T lymphocytopenia under exogenous thermal stress. Cancer 42:2794–2797PubMedCrossRef
5.
go back to reference Schmidt KL (1987) Hyperthermie und Fieber. Wirkungen bei Mensch und Tier. Klinik, Pathologie, Immunologie, Wirkungen auf Entzündungen. Hippokrates Verlag, Stuttgart Schmidt KL (1987) Hyperthermie und Fieber. Wirkungen bei Mensch und Tier. Klinik, Pathologie, Immunologie, Wirkungen auf Entzündungen. Hippokrates Verlag, Stuttgart
6.
go back to reference Schmidt KL, Simon E (2001) Thermotherapy of pain, trauma and inflammatory and degenerative rheumatic diseases. In: Kosaka M, Sugahara T, Schmidt KL, Simon E (eds) Thermotherapy for neoplasia, inflammation, and pain. Springer, Tokyo, pp 527–539 Schmidt KL, Simon E (2001) Thermotherapy of pain, trauma and inflammatory and degenerative rheumatic diseases. In: Kosaka M, Sugahara T, Schmidt KL, Simon E (eds) Thermotherapy for neoplasia, inflammation, and pain. Springer, Tokyo, pp 527–539
7.
go back to reference Schmidt KL (2004) Zur Wirkung der Ganzkörperhyperthermie auf Entzündungen und Immunreaktionen: experimentelle Grundlagen. Phys Rehab Kur Med 14:1–9CrossRef Schmidt KL (2004) Zur Wirkung der Ganzkörperhyperthermie auf Entzündungen und Immunreaktionen: experimentelle Grundlagen. Phys Rehab Kur Med 14:1–9CrossRef
8.
go back to reference Schleenbecker H, Schmidt KL (1998) Zur Wirkung einer iterativen milden Ganzkörper-Hyperthermie auf den Fibromyalgieschmerz. Phys Rehab Kur Med 8:113–117CrossRef Schleenbecker H, Schmidt KL (1998) Zur Wirkung einer iterativen milden Ganzkörper-Hyperthermie auf den Fibromyalgieschmerz. Phys Rehab Kur Med 8:113–117CrossRef
9.
go back to reference Hori T, Kaizuka Y, Takaki A, Katafuchi T (2001) Thermal stress and immunity. In: Kosaka M, Sugahara T, Schmidt KL, Simon E (eds) Thermotherapy for neoplasia, inflammation, and pain. Springer, Tokyo, pp 242–251 Hori T, Kaizuka Y, Takaki A, Katafuchi T (2001) Thermal stress and immunity. In: Kosaka M, Sugahara T, Schmidt KL, Simon E (eds) Thermotherapy for neoplasia, inflammation, and pain. Springer, Tokyo, pp 242–251
10.
go back to reference Lange U, Thielen G, Neeck G, Schmidt KL (2005) Einfluss der milden Hyperthermie auf die Blutspiegel von Kortisol und Lymphozytensubpopulationen bei Patienten mit ankylosierender Spondylitis und Gesunden. Phys Med Rehab Kuror 15:44–47CrossRef Lange U, Thielen G, Neeck G, Schmidt KL (2005) Einfluss der milden Hyperthermie auf die Blutspiegel von Kortisol und Lymphozytensubpopulationen bei Patienten mit ankylosierender Spondylitis und Gesunden. Phys Med Rehab Kuror 15:44–47CrossRef
11.
go back to reference Braun J (2002) Stadiensystem radiographischer Einteilung. In: Braun J, Sieper J (eds) Spondylitis ankylosans. Uni-Med, Bremen, p 114 Braun J (2002) Stadiensystem radiographischer Einteilung. In: Braun J, Sieper J (eds) Spondylitis ankylosans. Uni-Med, Bremen, p 114
12.
go back to reference Sobieska M, Stratz T, Samborski W et al (1993) Interleukin-6 (IL-6) after whole body cryotherapy and local hot mud pack treatment [letter]. Eur J Phys Med Rehabil 3:205 Sobieska M, Stratz T, Samborski W et al (1993) Interleukin-6 (IL-6) after whole body cryotherapy and local hot mud pack treatment [letter]. Eur J Phys Med Rehabil 3:205
13.
go back to reference Olszewski WL, Grzelak I, Ziolkowska A, Engeset A (1989) Effect of local hyperthermia on lymph immune cells and lymphokines of normal human skin. J Surg Oncol 41:109–116PubMedCrossRef Olszewski WL, Grzelak I, Ziolkowska A, Engeset A (1989) Effect of local hyperthermia on lymph immune cells and lymphokines of normal human skin. J Surg Oncol 41:109–116PubMedCrossRef
14.
go back to reference Bellometti S, Galzigna L (1998) Serum levels of a prostaglandin and a leukotriene after thermal mud pack therapy. J Investig Med 46:140–145PubMed Bellometti S, Galzigna L (1998) Serum levels of a prostaglandin and a leukotriene after thermal mud pack therapy. J Investig Med 46:140–145PubMed
15.
go back to reference Yoshioka A, Miyachi Y, Imamura S et al (1989) Suppression of contact sensitivity by local hyperthermia treatment due to reduced Langerhans cell population in mice. Br J Dermatol 120:493–501PubMedCrossRef Yoshioka A, Miyachi Y, Imamura S et al (1989) Suppression of contact sensitivity by local hyperthermia treatment due to reduced Langerhans cell population in mice. Br J Dermatol 120:493–501PubMedCrossRef
16.
go back to reference Huang YH, Haegerstrand A, Frostegård J (1996) Effects of in vitro hyperthermia on proliferative responses and lymphocyte activity. Clin Exp Immunol 103:61–66PubMedCrossRef Huang YH, Haegerstrand A, Frostegård J (1996) Effects of in vitro hyperthermia on proliferative responses and lymphocyte activity. Clin Exp Immunol 103:61–66PubMedCrossRef
17.
go back to reference Shen RN, Hornback NB, Shidnia H et al (1991) Whole body hyperthermia: a potent radioprotector in vivo. Int J Radiat Oncol Biol Phys 20:525–530PubMed Shen RN, Hornback NB, Shidnia H et al (1991) Whole body hyperthermia: a potent radioprotector in vivo. Int J Radiat Oncol Biol Phys 20:525–530PubMed
18.
go back to reference Tütüncü ZN, Turan M, Yüzbasioglu N, Karagülle MZ (1996) Changes in TNFα plasma levels in osteoarthritis patients under balneotherapy with acratothermal water. Phys Rehab Kur Med 6:80–82CrossRef Tütüncü ZN, Turan M, Yüzbasioglu N, Karagülle MZ (1996) Changes in TNFα plasma levels in osteoarthritis patients under balneotherapy with acratothermal water. Phys Rehab Kur Med 6:80–82CrossRef
19.
go back to reference Tütüncü ZN, Bilgie A, Kennedy LG, Calin A (1994) Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis. Ann Rheum Dis 53:425–426PubMedCrossRef Tütüncü ZN, Bilgie A, Kennedy LG, Calin A (1994) Interleukin-6, acute phase reactants and clinical status in ankylosing spondylitis. Ann Rheum Dis 53:425–426PubMedCrossRef
20.
go back to reference Gratacós J, Collado A, Filella X et al (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33:927–931PubMedCrossRef Gratacós J, Collado A, Filella X et al (1994) Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 33:927–931PubMedCrossRef
21.
go back to reference Falkenbach A, Herold M (1998) In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility. Rheumatol Int 18:103–106PubMedCrossRef Falkenbach A, Herold M (1998) In ankylosing spondylitis serum interleukin-6 correlates with the degree of mobility restriction, but not with short-term changes in the variables for mobility. Rheumatol Int 18:103–106PubMedCrossRef
22.
go back to reference Gratacós J, Collado A, Pons F et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 42:2319–2324PubMedCrossRef Gratacós J, Collado A, Pons F et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. Arthritis Rheum 42:2319–2324PubMedCrossRef
23.
go back to reference Bal A, Unlu E, Bahar G et al (2007) Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 26:211–215PubMedCrossRef Bal A, Unlu E, Bahar G et al (2007) Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 26:211–215PubMedCrossRef
24.
go back to reference Park MC, Lee SW, Choi ST et al (2007) Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 36:101–106PubMedCrossRef Park MC, Lee SW, Choi ST et al (2007) Serum leptin levels correlate with interleukin-6 levels and disease activity in patients with ankylosing spondylitis. Scand J Rheumatol 36:101–106PubMedCrossRef
25.
go back to reference Brandt J, Haibel H, Cornely D et al (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346–1352PubMedCrossRef Brandt J, Haibel H, Cornely D et al (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346–1352PubMedCrossRef
26.
go back to reference Lange U, Teichmann J, Stracke H (2000) Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res 5:507–511PubMed Lange U, Teichmann J, Stracke H (2000) Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res 5:507–511PubMed
27.
go back to reference Chou CT, Huo AP, Chang HN et al (2007) Cytokine production from peripheral blood mononuclear cells in patients with ankylosing spondylitis and their first-degree relatives. Arch Med Res 38:190–195PubMedCrossRef Chou CT, Huo AP, Chang HN et al (2007) Cytokine production from peripheral blood mononuclear cells in patients with ankylosing spondylitis and their first-degree relatives. Arch Med Res 38:190–195PubMedCrossRef
28.
go back to reference François RJ, Neure L, Sieper J, Braun J (2006) Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 65:713–720PubMedCrossRef François RJ, Neure L, Sieper J, Braun J (2006) Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 65:713–720PubMedCrossRef
29.
go back to reference Vazquez-Del MM, Garcia-Gonzalez A, Muñoz-Valle JF et al (2002) Interleukin 1beta (IL-1beta), IL-10, tumor necrosis factor-alpha, and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis. J Rheumatol 29:522–526PubMed Vazquez-Del MM, Garcia-Gonzalez A, Muñoz-Valle JF et al (2002) Interleukin 1beta (IL-1beta), IL-10, tumor necrosis factor-alpha, and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis. J Rheumatol 29:522–526PubMed
30.
go back to reference Rudwaleit M, Siegert S, Yin Z et al (2001) Low T cell production of TNFα and IFNγ in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 60:36–42PubMedCrossRef Rudwaleit M, Siegert S, Yin Z et al (2001) Low T cell production of TNFα and IFNγ in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 60:36–42PubMedCrossRef
31.
go back to reference Furst D, Breedveld FC, Kalden JR et al (2007) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66(Suppl III):iii2–iii22PubMedCrossRef Furst D, Breedveld FC, Kalden JR et al (2007) Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66(Suppl III):iii2–iii22PubMedCrossRef
32.
go back to reference Maini RN, Taylor PC, Szechinski J, CHARISMA Study Group et al (2006) Double-blind, randomized controlled trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–2829PubMedCrossRef Maini RN, Taylor PC, Szechinski J, CHARISMA Study Group et al (2006) Double-blind, randomized controlled trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–2829PubMedCrossRef
33.
go back to reference Wendling D, Racadot E, Toussirot E, Wijdenes J (1996) Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy. Br J Rheumatol 35:1330PubMedCrossRef Wendling D, Racadot E, Toussirot E, Wijdenes J (1996) Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy. Br J Rheumatol 35:1330PubMedCrossRef
34.
go back to reference Toussirot E, Lafforgue P, Boucraut J et al (1994) Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int 13:175–180PubMedCrossRef Toussirot E, Lafforgue P, Boucraut J et al (1994) Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int 13:175–180PubMedCrossRef
35.
go back to reference Tan AL, Marzo-Ortega H, O’Connor P et al (2004) Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 63:1041–1045PubMedCrossRef Tan AL, Marzo-Ortega H, O’Connor P et al (2004) Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 63:1041–1045PubMedCrossRef
36.
go back to reference Haibel H, Rudwaleit M, Listing J, Sieper J (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64:296–298PubMedCrossRef Haibel H, Rudwaleit M, Listing J, Sieper J (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64:296–298PubMedCrossRef
37.
go back to reference Bennett AN, Tan AL, Coates LC et al (2008) Sustained response to anakinra in ankylosing spondylitis. Rheumatology 47:223–224PubMedCrossRef Bennett AN, Tan AL, Coates LC et al (2008) Sustained response to anakinra in ankylosing spondylitis. Rheumatology 47:223–224PubMedCrossRef
Metadata
Title
The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis
Authors
Ingo H. Tarner
Ulf Müller-Ladner
Christine Uhlemann
Uwe Lange
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 4/2009
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-008-1059-x

Other articles of this Issue 4/2009

Clinical Rheumatology 4/2009 Go to the issue